This article is more than 5 years old. Information may no longer be current.

Icon Bioscience completes enrollment for phase 1 trial of CME treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SUNNYVALE, Calif. — Icon Bioscience has completed enrollment for a phase 1 safety and efficacy trial of its lead product, IBI-20089, in patients with cystoid macular edema associated with retinal vein occlusion and postoperative cataract surgery, the company announced in a press release.

Based on Icon's Verisome drug delivery platform technology, IBI-20089 is designed to last up to 1 year with a single intravitreal injection for ophthalmic indications, allowing physicians to tailor the duration of effect for each individual patient.

"We are pleased to have reached this important milestone. Our preliminary data confirms the safety and efficacy of our lead product, IBI-20089, as well as the versatility and flexibility of our underlying Verisome drug delivery technology," Vernon G. Wong, MD, founder of Icon, said in the release.